Clinical Trial Record

Return to Clinical Trials

Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors


2012-02


2017-12


2017-12


274

Study Overview

Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors

Pancreatic cancer is among the most serious human neoplasia and the most difficult to treat. Most patients present at diagnosis a non resectable, locally advanced or metastatic disease, with a median survival of 12 month. The aim of this study is the identification of diagnosis biomarkers, predictive of the therapeutic response. This project investigate the use of molecular analyses applied to pancreatic tumor cells collected by microbiopsy under ultrasound-endoscopy, and blood cells.

N/A

  • Pancreatic Tumor
  • PROCEDURE: suspected pancreatic tumor
  • PACAomics / IPC 2011-004

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2012-09-14  

N/A  

2018-08-10  

2012-09-21  

N/A  

2018-08-14  

2012-09-25  

N/A  

2018-08  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Other


Allocation:
Na


Interventional Model:
Single Group


Masking:
None


Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: suspected pancreatic tumor

Realization of pancreatic tumor biopsy and blood samples

PROCEDURE: suspected pancreatic tumor

  • Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
Primary Outcome MeasuresMeasure DescriptionTime Frame
BiomarkersGenomics, transcriptomics and proteomics analyses to determine presence or absence of biomarkerswithin twenty four hours
Secondary Outcome MeasuresMeasure DescriptionTime Frame
HistologyTo determine the histologic characteristics of the pancreatic tumorwithin twenty four hours

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:

  • Suspicion of pancreatic adenocarcinoma
  • Patient > 18 years old
  • Social Security affiliation
  • Signed informed consent

  • Exclusion Criteria:

  • Patient in emergency situation
  • Major person being the object of a legal protective measure or unable to express its consent

Collaborators and Investigators

This is where you will find people and organizations involved with this study.


    • PRINCIPAL_INVESTIGATOR: Marine GILABERT, MD, Institut Paoli-Calmettes

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    • Fraunhoffer NA, Abuelafia AM, Chanez B, Bigonnet M, Gayet O, Roques J, Chuluyan E, Dusetti N, Iovanna J. Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity. Cancer Commun (Lond). 2022 Nov;42(11):1212-1216. doi: 10.1002/cac2.12365. Epub 2022 Sep 30. No abstract available.
    • Fraunhoffer NA, Abuelafia AM, Dusetti N, Iovanna J. Limitation and challenges in using pancreatic cancer-derived organoids as a preclinical tool. Cancer Commun (Lond). 2022 Oct;42(10):1028-1031. doi: 10.1002/cac2.12335. Epub 2022 Jul 18. No abstract available.